



## **Alzinova presents promising data for the ALZ-101 vaccine at the international Alzheimer conference AD/PD™**

**Alzinova AB (publ) ("Alzinova" or "the Company") presents data and studies for the Company's vaccine candidate ALZ-101 at the international conference AD/PD™ held in Gothenburg on March 28 - April 1. The results from the studies show both long-term efficacy and that antibodies are present in the central nervous system, which is where the effect should be.**

Preclinical data on the vaccine candidate show that ALZ-101 has a long-lasting effect and that antibodies can be observed even six months after the last dose. Antibodies increase sharply after refill doses of the vaccine, suggesting that an immunological memory has been created by the immunization. In addition, antibodies can be observed in spinal fluid, suggesting that they reach the central nervous system in expected amounts. The vaccine thus appears to be effective even as a long-term (chronic) treatment. The poster also shows base line disease characteristics on all patients included in the ongoing phase 1b clinical trial. The conclusion is that ALZ-101 stimulates the production of antibodies for a long time, and that these can reach the brain in relevant amounts.

AD/PD™ - International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders - is an international conference on neurodegenerative diseases held in Gothenburg, Sweden, March 28 - April 1. The AD/PD™ conference has become an important scientific forum and event in the field of neurodegenerative diseases, attracting leading medical and scientific experts from around the world. Alzinova is there to network and present the Company's drug projects to Key Opinion Leaders, potential licensees and partners. In connection with the conference, Alzinova's Chief Scientific Officer Anders Sandberg will present a scientific poster summarizing preclinical data for the Company's vaccine candidate ALZ-101.

The poster will be available on Alzinova's website after the presentation.

**For more information, please contact:**

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*



### **About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

### **Attachments**

**Alzinova presents promising data for the ALZ-101 vaccine at the international Alzheimer conference AD/PD™**